Related stories
Amgen’s Repatha Posts $1.085 Billion in Third-Quarter Sales
Sales rose 37% year over year, driven by volume growth, the company said.
M impact | EQUITY | Nov 03, 2026, 09:43 PM UTC
Kadant Expects Q4 Revenue of $287.0M-$302.0M
M impact | EQUITY | Nov 03, 2026, 09:43 PM UTC
IFF Reports a Third-Quarter Loss as Net Sales Rise
IFF moved into a loss in the third quarter of 2026, while net sales increased.
M impact | EQUITY | Nov 03, 2026, 09:43 PM UTC
NGEx Minerals Receives Court Approval for Valle Ancho Spin-Out
L impact | EQUITY | Nov 03, 2026, 09:42 PM UTC
IFF Swings to Q3 Continuing-Operations Net Loss of $127 Million
M impact | EQUITY | Nov 03, 2026, 09:42 PM UTC
BioMarin Reports Third-Quarter Revenue of $1.02 Billion
Revenue rose 32% from $776.1 million a year earlier. Net loss widened to $122.8 million from $30.7 million, and diluted loss per share increased to $0.63 from $0.16.
M impact | EQUITY | Nov 03, 2026, 09:42 PM UTC